Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neural stem cell delivered oncolytic virus - Therabiologics

Next Previous
Drug Profile

Research programme: neural stem cell delivered oncolytic virus - Therabiologics

Alternative Names: TBX.OncV NSCs

Latest Information Update: 05 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TheraBiologics
  • Class Oncolytic viruses; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioma

Most Recent Events

  • 05 Sep 2023 Discontinued - Preclinical for Glioma in USA (Intracerebral) (https://www.google.com/search?q=Therabiologics&sca_esv=562712696&rlz=1C1GCEA_enIN1019IN1019&ei=Fwf3ZLecI66RseMPs6az8AE&ved=0ahUKEwj3g96_pZOBAxWuSGwGHTPTDB4Q4dUDCBA&uact=5&oq=Therabiologics&gs_lp=Egxnd3Mtd2l6LXNlcnAiDlRoZXJhYmlvbG9naWNzMgUQABiABEiWDVDaBFjQCHABeACQAQCYAb4BoAHfBKoBAzAuNLgBA8gBAPgBAcICBRAAGKIE4gMEGAEgQYgGAQ&sclient=gws-wiz-serp)
  • 28 Jun 2020 No recent reports of development identified for preclinical development in Glioma in USA (Intracerebral, Injection)
  • 16 May 2016 Preclinical trials in Glioma in USA (Intracerebral) before May 2016

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top